Transcript of Investors/Analyst meet on Q1 FY 27 Financial Results

August 20, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Bandra-Kurla Complex, Mumbai – 400001. Bandra (East), Mumbai – 400051. Scrip Code: 524404 Symbol: MARKSANS Subject: Transcript of investor(s)/analyst(s) meet – Q1FY27 Financial Results Dear Sir/Madam, Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed the transcript of the investor(s) / analyst(s) meet on Q1FY27 financial results held on August 13, 2026. The above information is also available on the website of the Company i.e. https://www.marksanspharma.com/earnings-call-transcripts.html We request you to take the aforesaid on records. Thanking you. Yours faithfully, For Marksans Pharma Limited Harshavardhan Panigrahi Company Secretary Encl: As above Marksans Pharma Ltd. 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: companysecretary@marksanspharma.com www.marksanspharma.com “Marksans Pharma Limited Q1 FY27 Earnings Conference Call” August 13, 2026 MANAGEMENT: MR. MARK SALDANHA – FOUNDER, CHAIRMAN AND MANAGING DIRECTOR – MARKSANS PHARMA LIMITED MR. JITENDRA SHARMA – CHIEF FINANCIAL OFFICER – MARKSANS PHARMA LIMITED MODERATOR: MR. NITIN AGARWAL – DAM CAPITAL Page 1 of 15 Marksans Pharma Limited August 13, 2026 Moderator: Ladies and gentlemen, good day and welcome to Marksans Pharma Q1 FY27 Earnings Conference Call, hosted by DAM Capital Advisors Limited. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Nitin Agarwal. Thank you, and over to you, sir. Nitin Agarwal: Warm welcome to Marksans Pharma's Q1 FY27 Post Results Earnings Call hosted by DAM Capital Advisors Limited. On the call today, we have representing Marksans Pharma, Mr. Mark Saldanha, Founder and Chairman and Managing Director, and Mr. Jitendra Sharma, Chief Financial Officer. I'll hand over the call to Mark to make the opening comments and then we'll open the floor for questions from there on. Please go ahead, sir. Mark Saldanha: Thank you, Nitin. Good afternoon, everyone and thank you for joining us for our Q1 FY27 earnings conference call. We sincerely appreciate your interest and continued support for the company. Q1 FY27 has been a very strong start to the year for Marksans. We delivered INR841 crores of revenue, up 35.6% year-on-year, with our highest-ever quarterly EBITDA of INR213 crores and highest ever quarterly PAT of INR159 crores, alongside our cash balance crossing INR1,000 crores for the first time. We've been investing in our products, manufacturing capabilities, customer relationships, and international presence for several years now. And we are increasingly seeing these investments translate into growth, profitability, and cash generation. Europe has been a strategic highlight of the quarter. UK and Europe delivered the highest ever quarterly revenue of INR356 crores, growing 74.7% year-on-year. Over the last several months in Europe, we have moved from our primary existing channels to building our own front-end presence across key regulated markets. During the quarter, we completed the acquisition of QliniQ B.V in Netherlands, which contributed approximately INR44 crores of revenue in Q1. Even excluding this contribution, the region grew strongly by 53.1% year-on-year. We then completed the acquisition of ABCnow GmbH, Germany with consolidation commencing from Q2. Alongside these acquisitions, we have established Marksans Pharma Europe in Ireland and Marksans Pharma GmbH in Germany. Europe is becoming an important new growth market for Marksans, and we remain focused on progressively scaling our presence across the region. Talking about our other key regions, in North America, we delivered INR377 crores of revenue, growing 15.1% year-on-year. This quarter saw a softer demand through the summer months, in Page 2 of 15 Marksans Pharma Limited August 13, 2026 line with the normal seasonal pattern. Price erosion in our Rx portfolio remained in single digits, and in the coming quarters, we expect momentum to strengthen. We have also established our presence in Canada with product filings underway. In Australia and New Zealand, we delivered INR88 crores of revenue, up 53.7% year-on-year. This was in line with our normal seasonal pattern, following a particularly strong fourth quarter during the Southern Hemisphere winter. The underlying business remains healthy, and we expect momentum to build as we move through the year. The improvement in the company's profitability is equally encouraging. The benefits of operating platform we have been building over the last several years are increasingly visible in our profitability. Our focus for the rest of FY27 is clear. Carry this momentum forward, scale across geographies, accelerate new product launches, build out the European market, and continue improving the profitability and cash generating ability of the business. We remain disciplined in how we allocate capital and selective about our inorganic opportunities. We remain confident about creating a business that is scalable, resilient, and positioned to deliver sustainable long-term value for all our stakeholders. With this, I hand it over to Jitendra, who will take you through the financial performance in detail. Jitendra Sharma: Thank you, sir. Good afternoon, everyone. Let me take you through the financial performance for Q1 FY27. Operating revenue for Q1 FY27 stood at INR840.8 crores, up 35.6% year-on-year from INR620 crores in Q1 of FY26. North America remained our largest market, contributing INR377 crores, up 15.1% year-on- year and accounting for approximately 45% of consolidated revenue. UK and Europe delivered INR356 crores, representing 74.7% year-on-year growth and approximately 42% of consolidated revenue. This was the highest ever quarterly revenue for the region. Europe also began contributing meaningfully during the quarter, following the acquisition and consolidation of QliniQ, while the underlying UK business continued to show strong momentum. Australia and New Zealand delivered INR88 crores, up 53.7% year-on-year. The sequential moderation was in line with the normal seasonal pattern following a particularly strong fourth quarter. The underlying business remains healthy and we expect momentum to build as we move through the year. Rest of World contributed INR20 crores during the quarter. Gross profit stood at INR497.3 crores, up 38.9% year-on-year from INR358.2 crores. While gross margin improved to 59.1% from 57.8%, an expansion of 138 basis points. Sequentially, gross profit increased from INR465 crores, with gross margin expanding by 478 basis points. The improvement was supported by favorable product mix, lower cost materials held in the inventory, and favorable foreign exchange. EBITDA stood at INR213 crores, compared with INR100.1 crores in Q1 FY26, representing 112.8% year-on-year growth. EBITDA margin expanded to 25.3% from 16.1%, an improvement Page 3 of 15 Marksans Pharma Limited August 13, 2026 of 919 basis points. Sequentially, EBITDA increased from INR195.4 crores, while EBITDA margin expanded by 251 basis points. The improvement reflects the benefit of higher gross margin together with operating leverage. Profit after-tax stood at INR159.4 crores compared with INR58.2 crores in Q1 FY26, representing a 173.9% year-on-year increase. PAT margin improved to 18.4% from 9.3% sequentially, PAT increased from INR149 cr [Showing first 8,000 characters — download PDF for full document]